We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$10.2B
AUM Growth
+$793M
Cap. Flow
+$230M
Cap. Flow %
2.25%
Top 10 Hldgs %
30.33%
Holding
229
New
13
Increased
77
Reduced
41
Closed
15

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$74.7M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$44M
3
IQV icon
IQVIA
IQV
+$40.5M
4
MGNX icon
MacroGenics
MGNX
+$39.5M
5
SAGE
Sage Therapeutics
SAGE
+$39.1M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$222M
2
MRNA icon
Moderna
MRNA
+$47.8M
3
CI icon
Cigna
CI
+$47.8M
4
BMY icon
Bristol-Myers Squibb
BMY
+$40.5M
5
DVA icon
DaVita
DVA
+$39.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.41%
2 Industrials 0.94%
3 Technology 0.31%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMDX icon
101
Transmedics
TMDX
$2.5B
$24.2M 0.24%
729,989
-12,211
-2% -$338K
AXSM icon
102
Axsome Therapeutics
AXSM
$11.8B
$23.7M 0.23%
+352,021
New +$21.1M
PRVA icon
103
Privia Health
PRVA
$3.38B
$23.3M 0.23%
+525,000
New +$19.4M
OM icon
104
Outset Medical
OM
$75.4M
$22.8M 0.22%
30,471
+13,423
+79% +$10.3M
RMD icon
105
ResMed
RMD
$28.4B
$21.7M 0.21%
88,145
– –
ZLAB icon
106
Zai Lab
ZLAB
$2.29B
$21.6M 0.21%
122,000
+35,500
+41% +$5.71M
TMO icon
107
Thermo Fisher Scientific
TMO
$197B
$21.2M 0.21%
41,974
+5,400
+15% +$2.55M
INGN icon
108
Inogen
INGN
$174M
$18.3M 0.18%
280,863
– –
AVTR icon
109
Avantor
AVTR
$7.39B
$18.2M 0.18%
512,216
– –
WVE icon
110
Wave Life Sciences
WVE
$1.13B
$17.3M 0.17%
2,602,858
– –
EAR
111
DELISTED
Eargo, Inc. Common Stock
EAR
$17.3M 0.17%
21,703
+2,310
+12% +$1.94M
CELL
112
DELISTED
PhenomeX Inc. Common Stock
CELL
$17.3M 0.17%
385,014
+6,011
+2% +$279K
LEGN icon
113
Legend Biotech
LEGN
$4.37B
$16M 0.16%
390,163
-213,080
-35% -$7.24M
NBP
114
NovaBridge Biosciences American Depositary Shares
NBP
$208M
$15.4M 0.15%
183,457
-15,000
-8% -$990K
OSCR icon
115
Oscar Health
OSCR
$8.92B
$14.9M 0.15%
694,136
+239,562
+53% +$5.73M
AMED
116
DELISTED
Amedisys
AMED
$14.8M 0.14%
60,487
– –
GTH
117
DELISTED
Genetron Holdings Limited ADS
GTH
$14.6M 0.14%
241,046
+30,350
+14% +$1.87M
BNR
118
Burning Rock Biotech
BNR
$105M
$14.4M 0.14%
48,989
+5,696
+13% +$1.69M
CDNA icon
119
CareDx
CDNA
$2.05B
$13.6M 0.13%
148,871
-41,500
-22% -$3.3M
CVS icon
120
CVS Health
CVS
$138B
$13.4M 0.13%
160,148
+35,600
+29% +$2.92M
QTTB icon
121
Q32 Bio
QTTB
$363M
$12.6M 0.12%
96,507
– –
NPCE icon
122
Neuropace
NPCE
$546M
$12.1M 0.12%
+507,930
New +$11.8M
XENT
123
DELISTED
Intersect ENT, Inc
XENT
$10.6M 0.1%
617,968
– –
XRAY icon
124
Dentsply Sirona
XRAY
$2.78B
$10.1M 0.1%
159,129
– –
LH icon
125
Labcorp
LH
$23.2B
$9.99M 0.1%
42,137
+25,608
+155% +$5.83M
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2021 Portfolio in Review

As of Q2 2021, Bellevue Group held 229 positions worth $10.2B, up 8.4% from $9.45B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q2 2021 filing shows 13 new, 77 increased, 41 reduced and 15 closed positions. Its largest new stake was Adaptive Biotechnologies: 962,352 shares worth $39.3M. The largest sale was Alexion Pharmaceuticals, an estimated $222M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2021 buy was Adaptive Biotechnologies: 962,352 shares worth $39.3M.
  • Bellevue Group added most to Vertex Pharmaceuticals in Q2 2021, an estimated $74.7M increase.
  • Bellevue Group's biggest Q2 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $222M.
  • Bellevue Group fully exited DaVita in Q2 2021, selling an estimated $39.6M.
  • Bellevue Group's ten largest holdings make up 30% of its $10.2B portfolio in Q2 2021.
  • Bellevue Group opened 13 new positions and closed 15 in Q2 2021.
  • Bellevue Group's portfolio value rose 8.4% quarter-over-quarter to $10.2B.

Based on Bellevue Group's 13F filing for Q2 2021, filed 12 Aug 2021.